Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

por Landgren, C. Ola, Chari, Ajai, Cohen, Yael C., Spencer, Andrew, Voorhees, Peter, Estell, Jane A., Sandhu, Irwindeep, Jenner, Matthew W., Williams, Catherine, Cavo, Michele, van de Donk, Niels W. C. J., Beksac, Meral, Moreau, Philippe, Goldschmidt, Hartmut, Kuppens, Steven, Bandekar, Rajesh, Clemens, Pamela L., Neff, Tobias, Heuck, Christoph, Qi, Ming, Hofmeister, Craig C.
Publicado 2020

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

por Bachy, Emmanuel, Seymour, John F., Feugier, Pierre, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Catalano, John V., Brice, Pauline, Lemonnier, François, Martin, Alejandro, Casasnovas, Olivier, Pedersen, Lars M., Dorvaux, Véronique, Simpson, David, Leppa, Sirpa, Gabarre, Jean, da Silva, Maria G., Glaisner, Sylvie, Ysebaert, Loic, Vekhoff, Anne, Intragumtornchai, Tanin, Le Gouill, Steven, Lister, Andrew, Estell, Jane A., Milone, Gustavo, Sonet, Anne, Farhi, Jonathan, Zeuner, Harald, Tilly, Hervé, Salles, Gilles
Publicado 2019